Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

BACKGROUND: Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) is an unexplored therapy amidst the rapidly evolving spectrum of medical therapies for COVID-19 and is expected to counter the three most life-threatening consequences of COVID-19 including lung injury by the virus, cytokine s...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:EClinicalMedicine
المؤلفون الرئيسيون: Ali, Shaukat, Uddin, Syed Muneeb, Shalim, Elisha, Sayeed, Muneeba Ahsan, Anjum, Fatima, Saleem, Farah, Muhaymin, Sheikh Muhammad, Ali, Ayesha, Ali, Mir Rashid, Ahmed, Iqra, Mushtaq, Tehreem, Khan, Sadaf, Shahab, Faisal, Luxmi, Shobha, Kumar, Suneel, Arain, Habiba, Khan, Mujtaba, Khan, Abdul Samad, Mehmood, Hamid, Rasheed, Abdur, Jahangeer, Ashraf, Baig, SaifUllah, Quraishy, Saeed
التنسيق: Artigo
اللغة:Inglês
منشور في: Elsevier 2021
الموضوعات:
Research Paper
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177439/
https://ncbi.nlm.nih.gov/pubmed/34109306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100926
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة